PortalPublikationenIntraventricular methotrexate as part of primary therapy for...

Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy

Standard

Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. / Pompe, Raisa S; von Bueren, André O; Mynarek, Martin; von Hoff, Katja; Friedrich, Carsten; Kwiecien, Robert; Treulieb, Wiebke; Lindow, Christine; Deinlein, Frank; Fleischhack, Gudrun; Kuehl, Joachim; Rutkowski, Stefan.

in: EUR J CANCER, Jahrgang 51, Nr. 17, 11.2015, S. 2634-2642.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Pompe, RS, von Bueren, AO, Mynarek, M, von Hoff, K, Friedrich, C, Kwiecien, R, Treulieb, W, Lindow, C, Deinlein, F, Fleischhack, G, Kuehl, J & Rutkowski, S 2015, 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy', EUR J CANCER, Jg. 51, Nr. 17, S. 2634-2642. https://doi.org/10.1016/j.ejca.2015.08.009

APA

Pompe, R. S., von Bueren, A. O., Mynarek, M., von Hoff, K., Friedrich, C., Kwiecien, R., Treulieb, W., Lindow, C., Deinlein, F., Fleischhack, G., Kuehl, J., & Rutkowski, S. (2015). Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. EUR J CANCER, 51(17), 2634-2642. https://doi.org/10.1016/j.ejca.2015.08.009

Vancouver

Pompe RS, von Bueren AO, Mynarek M, von Hoff K, Friedrich C, Kwiecien R et al. Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. EUR J CANCER. 2015 Nov;51(17):2634-2642. https://doi.org/10.1016/j.ejca.2015.08.009

Bibtex

@article{4c211b0000884990a3bcbe0e60fdd180,
title = "Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy",
abstract = "BACKGROUND: To assess feasibility, acute toxicity, and efficacy of intraventricular methotrexate administered as part of the primary therapy in medulloblastoma.METHODS: From 2001 to 2007, 240 patients <22years from 61 treatment centres were registered. Patients received 2-3 cycles of intraventricular methotrexate with systemic chemotherapy in three different treatment arms of the prospective multicentre trial HIT2000 (150 children >4years with metastatic, 59 <4years with non-metastatic, 31 <4years with metastatic medulloblastoma).RESULTS: 211 patients received an intraventricular access device with a subcutaneous reservoir for the application of chemotherapy. Reservoir-associated complications were documented in 57 (27%) patients, mostly due to infection (n=32) and reservoir malfunction (n=19), requiring removal in 39 (18%) patients. Acute neurotoxicity likely associated with intraventricular MTX was observed in 9/202 documented patients. Toxicity was usually mild, apart from one therapy-associated death due to toxic oedema followed by seizures. Of 519 treatment cycles including intraventricular methotrexate, 226 (43%) were reduced or omitted, most frequently due to the absence of an intraventricular device. Survival rates were higher in patients receiving ⩾75% of the scheduled intraventricular methotrexate dose compared to those receiving <75% in both univariate and multivariate models (event-free survival (EFS), 61.5 versus 46.2%, p=0.004; OS, 75.5% versus 60.4%, p=0.015; hazard ratio: EFS 1.723, p=0.016; OS 1.648, p=0.051).CONCLUSION: Intraventricular methotrexate therapy was feasible and mostly well tolerated. Infections were the most frequent complication. A higher cumulative dose of intraventricular methotrexate was associated with better survival. Further evaluation of efficacy and late effects is warranted.",
author = "Pompe, {Raisa S} and {von Bueren}, {Andr{\'e} O} and Martin Mynarek and {von Hoff}, Katja and Carsten Friedrich and Robert Kwiecien and Wiebke Treulieb and Christine Lindow and Frank Deinlein and Gudrun Fleischhack and Joachim Kuehl and Stefan Rutkowski",
note = "Copyright {\textcopyright} 2015 Elsevier Ltd. All rights reserved.",
year = "2015",
month = nov,
doi = "10.1016/j.ejca.2015.08.009",
language = "English",
volume = "51",
pages = "2634--2642",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "17",

}

RIS

TY - JOUR

T1 - Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy

AU - Pompe, Raisa S

AU - von Bueren, André O

AU - Mynarek, Martin

AU - von Hoff, Katja

AU - Friedrich, Carsten

AU - Kwiecien, Robert

AU - Treulieb, Wiebke

AU - Lindow, Christine

AU - Deinlein, Frank

AU - Fleischhack, Gudrun

AU - Kuehl, Joachim

AU - Rutkowski, Stefan

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/11

Y1 - 2015/11

N2 - BACKGROUND: To assess feasibility, acute toxicity, and efficacy of intraventricular methotrexate administered as part of the primary therapy in medulloblastoma.METHODS: From 2001 to 2007, 240 patients <22years from 61 treatment centres were registered. Patients received 2-3 cycles of intraventricular methotrexate with systemic chemotherapy in three different treatment arms of the prospective multicentre trial HIT2000 (150 children >4years with metastatic, 59 <4years with non-metastatic, 31 <4years with metastatic medulloblastoma).RESULTS: 211 patients received an intraventricular access device with a subcutaneous reservoir for the application of chemotherapy. Reservoir-associated complications were documented in 57 (27%) patients, mostly due to infection (n=32) and reservoir malfunction (n=19), requiring removal in 39 (18%) patients. Acute neurotoxicity likely associated with intraventricular MTX was observed in 9/202 documented patients. Toxicity was usually mild, apart from one therapy-associated death due to toxic oedema followed by seizures. Of 519 treatment cycles including intraventricular methotrexate, 226 (43%) were reduced or omitted, most frequently due to the absence of an intraventricular device. Survival rates were higher in patients receiving ⩾75% of the scheduled intraventricular methotrexate dose compared to those receiving <75% in both univariate and multivariate models (event-free survival (EFS), 61.5 versus 46.2%, p=0.004; OS, 75.5% versus 60.4%, p=0.015; hazard ratio: EFS 1.723, p=0.016; OS 1.648, p=0.051).CONCLUSION: Intraventricular methotrexate therapy was feasible and mostly well tolerated. Infections were the most frequent complication. A higher cumulative dose of intraventricular methotrexate was associated with better survival. Further evaluation of efficacy and late effects is warranted.

AB - BACKGROUND: To assess feasibility, acute toxicity, and efficacy of intraventricular methotrexate administered as part of the primary therapy in medulloblastoma.METHODS: From 2001 to 2007, 240 patients <22years from 61 treatment centres were registered. Patients received 2-3 cycles of intraventricular methotrexate with systemic chemotherapy in three different treatment arms of the prospective multicentre trial HIT2000 (150 children >4years with metastatic, 59 <4years with non-metastatic, 31 <4years with metastatic medulloblastoma).RESULTS: 211 patients received an intraventricular access device with a subcutaneous reservoir for the application of chemotherapy. Reservoir-associated complications were documented in 57 (27%) patients, mostly due to infection (n=32) and reservoir malfunction (n=19), requiring removal in 39 (18%) patients. Acute neurotoxicity likely associated with intraventricular MTX was observed in 9/202 documented patients. Toxicity was usually mild, apart from one therapy-associated death due to toxic oedema followed by seizures. Of 519 treatment cycles including intraventricular methotrexate, 226 (43%) were reduced or omitted, most frequently due to the absence of an intraventricular device. Survival rates were higher in patients receiving ⩾75% of the scheduled intraventricular methotrexate dose compared to those receiving <75% in both univariate and multivariate models (event-free survival (EFS), 61.5 versus 46.2%, p=0.004; OS, 75.5% versus 60.4%, p=0.015; hazard ratio: EFS 1.723, p=0.016; OS 1.648, p=0.051).CONCLUSION: Intraventricular methotrexate therapy was feasible and mostly well tolerated. Infections were the most frequent complication. A higher cumulative dose of intraventricular methotrexate was associated with better survival. Further evaluation of efficacy and late effects is warranted.

U2 - 10.1016/j.ejca.2015.08.009

DO - 10.1016/j.ejca.2015.08.009

M3 - SCORING: Journal article

C2 - 26346136

VL - 51

SP - 2634

EP - 2642

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

IS - 17

ER -